Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed ALN-TTR02, a potential treatment for a genetic mutation of the transthyretin gene, reduced serum TTR protein levels in a way that was "rapid, dose dependent, durable, and specific after just a single dose."
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Fri, 9:16AM)
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs